The decision caps “a rigorous review” of the vaccine’s safety and effectiveness, June Raine, chief executive of the Medicines and Healthcare Products Regulatory Agency, said in a statement Thursday.
It’s unclear what plans the U.K., which has approved another five coronavirus immunizations, has for the shot. The product suffered a blow when a study testing seven different vaccines as boosters found Valneva’s was one of those that raised antibody levels the least. The research was conducted before omicron became ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.